Skip to content

Manufacturing & Distribution

Smart Pharmaceutical Factory – Regulatory Compliance Framework

  • Manufacturing & Distribution
  • 1 min read

A Smart Pharmaceutical Factory is often associated with advanced automation, connected equipment, and digital workflows.

But technology alone does not make a factory “smart.”

What truly defines a Smart Pharmaceutical Factory is its ability to operate in a fully compliant, controlled, and inspection-ready environment — by design.

As manufacturers adopt Batch Control, MES/EBR, BMS/EMS, SCADA, and real-time monitoring platforms, they also inherit increased regulatory responsibility.

Digitalization amplifies risk if compliance is not built into the architecture from day one.

That’s why a Smart Pharmaceutical Factory must be supported by a comprehensive Regulatory Compliance Framework — one that connects people, processes, and technology across the entire system lifecycle.

Industries

Related

More on this subject

Part 11 applies to electronic records that a predicate rule such as 21 CFR 211 requires. For a BMS or EMS, name the rule behind each point: GMP-critical monitoring usually belongs in a validated EMS. For EU export, Annex 11 has no predicate-rule test, so the BMS still needs a risk assessment.

InsightRead

Periodic user-access review on SCADA and EMS

Individual logins make records attributable, but user lists drift as people move and leave. A periodic access review exports users and roles from the system, checks them against HR's leavers and movers, justifies every admin or generic account and is signed with its corrections, the record an inspector will ask for.

InsightRead

21 CFR Part 11 and EU GMP Annex 11 overlap on validation, access control and audit trails but differ in emphasis: Part 11 on electronic signatures, Annex 11 on a risk-based system lifecycle. Fixing the destination market in the design basis means the URS and validation plan for BMS, EMS and SCADA are written once.

Read